Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Aaron Bartlone as its chief operating officer; Bartlone has been the COO for Cybin’s U.S. subsidiary since March 2021. Bartlone has gathered impressive experience in his three-decade career, specifically in driving novel therapeutics through clinical development into global markets. He has worked in product development, commercial operations, quality assurance and regulatory affairs and has served in a variety of quality, safety, managerial, development and health positions at both UCB Inc., a global biopharmaceutical company, and Eli Lilly. According to the announcement, Bartlone has been personally involved in driving more than 25 molecular therapies and drug-device combination products to the global marketplace; he has also developed global teams of more than 1,000 colleagues in 50 countries. “Aaron’s leadership and expertise have contributed immensely to Cybin’s clinical accomplishments across its drug-development programs, including progressing the ongoing phase 1/2a study of CYB003, and the phase 1 CYB004-E study,” said Cybin CEO Doug Drysdale in the press release. “Aaron’s significant experience in regulatory, commercial and clinical operations will continue to be an asset as Cybin advances its programs. We are pleased to appoint Aaron as chief operating officer of Cybin Inc. and view this as a key step in strengthening the company’s execution as we continue to advance our clinical trials towards data readouts later this year.”
In addition, the company announced that its chief medical officer, Amir Inamdar, MBBS, DNB (Psych), MFPM, would be presenting at the PSYCH Symposium 2023. The one-day event is scheduled for July 6, 2023, in London. According to the announcement, Inamdar will be a featured fireside chat speaker. His presentation, which is titled “Challenges in Psychedelic Drug Development,” is slated to begin at 10:30 a.m. GMT. “I look forward to speaking at the PSYCH Symposium, where we will discuss some of the key issues facing investigators and drug developers in the conduct of research with psychedelics,” said Cybin chief medical officer Amir Inamdar in the press release. “As we continue to navigate these important conversations, we are encouraged by the recent FDA draft guidelines for psychedelic drug development, which are a step in the right direction in bringing these medicines to people who need them the most.”
To view the full press releases, visit https://ibn.fm/xDdpZ and https://ibn.fm/JQtcZ
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
